Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Teva Wins Generics Firm Ratiopharm
by Michael McCoy
March 22, 2010
| A version of this story appeared in
Volume 88, Issue 12
Israel's Teva Pharmaceutical Industries has agreed to acquire the German generic drugmaker Ratiopharm for nearly $5 billion. Teva calls Ratiopharm the number six generic drug company worldwide. The combined firm would have had 2009 sales of $16.2 billion, a 17% increase for Teva. Already the world's largest generics company, Teva says the deal will make it the European generics leader as well. According to published reports, Pfizer and the Icelandic generics firm Actavis were also bidders for Ratiopharm, which is being sold by Germany's Merckle family to help settle debts.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter